A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

NCT 06830850

Brief Introduction

To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of 5041-103 in Subjects with Metastatic Castration-resistant Prostate Cancer.

Intervention/Treatment

• Drug: HRS-5041 Single dose of HRS-5041 orally administered

Inclusion Criteria

1. Ability to understand the trial procedures and possible adverse events, voluntarily participate in the trial.
2. Adequate bone marrowsoft, spongy tissue found in bones that makes blood cells and other vital organ functions
3. Adequate liver function tests
4. Metastatic Castration-resistant Prostate Cancer